Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Regional Outlook | Forecast 2023-2030
Ophthalmic drugs,
including those for conditions like glaucoma, dry eye, retinal disorders, and
infections, constitute a substantial segment of the pharmaceutical market. This
industry's growth is due to several factors, one of them being the increasing
prevalence of eye disorders globally. As the aging population grows and
lifestyles evolve, the incidence of eye-related issues has surged,
necessitating a corresponding rise in demand for effective pharmaceutical
interventions. Thus, the global ophthalmic drugs market plays a pivotal role in
addressing various eye disorders and diseases, contributing significantly to
the overall healthcare landscape.
According to Triton Market Research’s report, the Global Ophthalmic Drugs Market was valued at $34547.84 million in 2022 and is expected to reach $58681.41 million by 2030, growing at a CAGR of 6.64% during the forecast period, 2023-2030.
Click here to check out our blog on the Global Ophthalmic Drugs Market
MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND OPPORTUNITIES
Factors such as innovations in drug delivery systems and advanced
research drive the growth of the ophthalmic drugs market.
This results in sustained-release implants and improved formulations that
enhance treatment efficacy and patient compliance. Additionally, the
development of biologics and gene therapies for ocular diseases represents a
frontier of innovation within the industry. These advancements not only
contribute to the expansion of treatment options but also foster collaborations
between pharmaceutical companies and research institutions.
However, stringent regulatory requirements for drug
approvals hampers the ophthalmic drugs market’s progress.
These norms impede the swift introduction of new ophthalmic drugs to the
market. Additionally, the high costs associated with research and development,
coupled with the complexity of clinical trials, can pose financial challenges
for smaller market players. Economic factors, such as reimbursement issues and
the high cost of certain ophthalmic drugs, limit patient access, thereby
affecting market growth.
Despite these challenges, an increase in approvals for innovative ophthalmic therapies presents a significant opportunity. This facilitates tailored treatments based on patient’s individual characteristics, such as their genetic makeup. Furthermore, the growing adoption of tele-ophthalmology and digital health technologies opens avenues for remote patient monitoring, early diagnosis, and improved accessibility to healthcare services, particularly in underserved regions.
Report scope can be customized per your requirements - Request Free Sample Report
KEY GEOGRAPHIES COVERED:
• North America: United States and Canada
• Europe: United Kingdom, France,
Germany, Spain, Italy, Poland, and Rest of Europe
• Asia-Pacific: China, Japan, India,
Australia & New Zealand, South Korea, ASEAN Countries, and Rest of
Asia-Pacific
• Latin America: Brazil, Mexico, and Rest
of Latin America
• Middle East and Africa: Saudi Arabia,
Turkey, United Arab Emirates, South Africa, and Rest of Middle East &
Africa
SEGMENTATION ANALYSIS – OPHTHALMIC DRUGS MARKET:
• Market by
Type:
o
By Prescription Drugs
o Over-The-Counter Drugs
• Market by
Condition:
o Dry Eye
o Glaucoma
o Infection/Inflammation/Allergies
o Retinal Disorder
• Wet-Age Related Macular Degeneration
• Dry-Age Related Macular Degeneration
• Diabetic Retinopathy
• Other Retinal Disorders
o Other Conditions
Dry eye is a common eye disorder that
occurs when the eyes do not produce enough tears. The symptoms may vary in
severity from person to person. Common symptoms include dryness, burning or
stinging, redness, blurred vision, sensitivity to light, watery eyes, and
discomfort with contact lenses. It is prevalent in the North American
population, where 5% to 30% of the adult population experiences dry eye
symptoms.
• Market
by Therapeutic Type:
o Anti-Glaucoma
o Anti-Infection
o Anti-Inflammatory
o Anti-Allergy
o Other Therapeutic Types
The anti-inflammatory therapeutic class
comprises a group of medications specifically used to reduce eye inflammation. These medications formulated as
ophthalmic solutions, eye drops, ointments, gels, or intraocular injections work
by suppressing the inflammatory response within the eye tissues. By using
anti-inflammatory medications, healthcare professionals aim to alleviate these
symptoms, promote healing, and prevent further damage to the eye.
• Market by Delivery Method:
o Gels
o Eye Solutions & Suspensions
o Capsules & Tablets
o Eye Drops
o Ointments
• Market by Channel:
o Hospital Pharmacies
o Drug Stores
o Online Pharmacies
o Other Channels
COMPETITIVE
LANDSCAPE:
The competitive
landscape helps dive into data about the key players in the ophthalmic drugs
market. The strategic initiatives for each of the companies considered have
been covered in detail.
Mergers & Acquisitions (December 2022): Johnson & Johnson and Abiomed Inc
Johnson & Johnson
completed its acquisition with Abiomed Inc. The latter operates as a standalone
business within Johnson & Johnson’s MedTech segment. The completion of this
acquisition allows Johnson & Johnson MedTech to expand its portfolio in the
high-growth cardiovascular markets.
Product
Launches (December 2022): Thea Pharma
Thea Pharma Inc
announced the US Food and Drug Administration (FDA) approval for the New Drug Application
(NDA) of IYUZEH™ (latanoprost ophthalmic solution) 0.005% for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG)
or ocular hypertension (OHT).
KEY BENEFITS OF THE REPORT:
· Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.
· Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.
· The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.
· The scope of the market report comprises the current scenario of the global ophthalmic drugs market, along with the detailed overview of the industry outlook, market dynamics, segmentation analysis, regional outlook, and competitive landscape for the period 2023-2030.
FAQs:
Q 1) Which region holds the highest share in the global
ophthalmic drugs market?
The North American
region had the highest share of around 37% in 2022 in the global ophthalmic
drugs market.
Q 2) What is one notable trend in the ophthalmic drugs
market?
A noticeable trend is the
rising adoption of over-the-counter (OTC) ophthalmic drugs due to their
accessibility, contributing positively to the market’s revenue.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
OPHTHALMIC DRUGS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TECHNOLOGY
SNAPSHOT
2.2. IMPACT
ANALYSIS ON THE OPHTHALMIC DRUGS MARKET
2.2.1. COVID-19
IMPACT ON THE OPHTHALMIC DRUGS MARKET
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
MATURITY ANALYSIS
2.5. REGULATORY
FRAMEWORK
2.6. KEY
BUYING IMPACT ANALYSIS
2.7. KEY
MARKET STRATEGIES
2.7.1. COLLABORATIONS
2.7.2. PRODUCT
LAUNCHES
2.7.3. MERGERS
& ACQUISITIONS
2.8. MARKET
DRIVERS
2.8.1. AGING
POPULATION VULNERABLE TO EYE DISORDERS
2.8.2. PROGRESS
IN DRUG DELIVERY TECHNOLOGIES
2.8.3. ESCALATING
INCIDENCE OF OCULAR DISEASES
2.8.4. REIMBURSEMENT
POLICIES BY HEALTHCARE SYSTEMS
2.9. MARKET
CHALLENGES
2.9.1. CHALLENGING
TIMELINES FOR PRODUCTS APPROVAL
2.9.2. ADVERSE
EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE
2.10. MARKET
OPPORTUNITIES
2.10.1. SURGE
IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS
2.10.2. INCREASE
IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES
2.11. ANALYST
PERSPECTIVE
3. GLOBAL
OPHTHALMIC DRUGS MARKET – BY TYPE
3.1. PRESCRIPTION
DRUGS
3.2. OVER-THE-COUNTER
DRUGS
4. GLOBAL
OPHTHALMIC DRUGS MARKET – BY CONDITION
4.1. DRY
EYE
4.2. GLAUCOMA
4.3. INFECTION/INFLAMMATION/ALLERGIES
4.4. RETINAL
DISORDER
4.4.1. WET-AGE
RELATED MACULAR DEGENERATION
4.4.2. DRY-AGE
RELATED MACULAR DEGENERATION
4.4.3. DIABETIC
RETINOPATHY
4.4.4. OTHER
RETINAL DISORDERS
4.5. OTHER
CONDITIONS
5. GLOBAL
OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE
5.1. ANTI-GLAUCOMA
5.2. ANTI-INFECTION
5.3. ANTI-INFLAMMATORY
5.4. ANTI-ALLERGY
5.5. OTHER
THERAPEUTIC TYPES
6. GLOBAL
OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD
6.1. GELS
6.2. EYE
SOLUTIONS & SUSPENSIONS
6.3. CAPSULES
& TABLETS
6.4. EYE
DROPS
6.5. OINTMENTS
7. GLOBAL
OPHTHALMIC DRUGS MARKET – BY CHANNEL
7.1. HOSPITAL
PHARMACIES
7.2. DRUG
STORES
7.3. ONLINE
PHARMACIES
7.4. OTHER
CHANNELS
8. GLOBAL
OPHTHALMIC DRUGS MARKET – BY REGIONAL OUTLOOK
8.1. NORTH
AMERICA
8.1.1. MARKET
BY TYPE
8.1.2. MARKET
BY CONDITION
8.1.2.1. MARKET
BY RETINAL DISORDER
8.1.3. MARKET
BY THERAPEUTIC TYPE
8.1.4. MARKET
BY DELIVERY METHOD
8.1.5. MARKET
BY CHANNEL
8.1.6. COUNTRY
ANALYSIS
8.1.6.1. UNITED
STATES
8.1.6.1.1. UNITED
STATES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.1.6.2. CANADA
8.1.6.2.1. CANADA
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2. EUROPE
8.2.1. MARKET
BY TYPE
8.2.2. MARKET
BY CONDITION
8.2.2.1. MARKET
BY RETINAL DISORDER
8.2.3. MARKET
BY THERAPEUTIC TYPE
8.2.4. MARKET
BY DELIVERY METHOD
8.2.5. MARKET
BY CHANNEL
8.2.6. COUNTRY
ANALYSIS
8.2.6.1. UNITED
KINGDOM
8.2.6.1.1. UNITED
KINGDOM OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2.6.2. GERMANY
8.2.6.2.1. GERMANY
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2.6.3. FRANCE
8.2.6.3.1. FRANCE
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2.6.4. ITALY
8.2.6.4.1. ITALY
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2.6.5. SPAIN
8.2.6.5.1. SPAIN
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2.6.6. POLAND
8.2.6.6.1. POLAND
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2.6.7. REST
OF EUROPE
8.2.6.7.1. REST
OF EUROPE OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3. ASIA-PACIFIC
8.3.1. MARKET
BY TYPE
8.3.2. MARKET
BY CONDITION
8.3.2.1. MARKET
BY RETINAL DISORDER
8.3.3. MARKET
BY THERAPEUTIC TYPE
8.3.4. MARKET
BY DELIVERY METHOD
8.3.5. MARKET
BY CHANNEL
8.3.6. COUNTRY
ANALYSIS
8.3.6.1. CHINA
8.3.6.1.1. CHINA
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3.6.2. JAPAN
8.3.6.2.1. JAPAN
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3.6.3. INDIA
8.3.6.3.1. INDIA
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3.6.4. SOUTH
KOREA
8.3.6.4.1. SOUTH
KOREA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3.6.5. ASEAN
COUNTRIES
8.3.6.5.1. ASEAN
COUNTRIES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3.6.6. AUSTRALIA
& NEW ZEALAND
8.3.6.6.1. AUSTRALIA
& NEW ZEALAND OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3.6.7. REST
OF ASIA-PACIFIC
8.3.6.7.1. REST
OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.4. LATIN
AMERICA
8.4.1. MARKET
BY TYPE
8.4.2. MARKET
BY CONDITION
8.4.2.1. MARKET
BY RETINAL DISORDER
8.4.3. MARKET
BY THERAPEUTIC TYPE
8.4.4. MARKET
BY DELIVERY METHOD
8.4.5. MARKET
BY CHANNEL
8.4.6. COUNTRY
ANALYSIS
8.4.6.1. BRAZIL
8.4.6.1.1. BRAZIL
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.4.6.2. MEXICO
8.4.6.2.1. MEXICO
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.4.6.3. REST
OF LATIN AMERICA
8.4.6.3.1. REST
OF LATIN AMERICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5. MIDDLE
EAST AND AFRICA
8.5.1. MARKET
BY TYPE
8.5.2. MARKET
BY CONDITION
8.5.2.1. MARKET
BY RETINAL DISORDER
8.5.3. MARKET
BY THERAPEUTIC TYPE
8.5.4. MARKET
BY DELIVERY METHOD
8.5.5. MARKET
BY CHANNEL
8.5.6. COUNTRY
ANALYSIS
8.5.6.1. UNITED
ARAB EMIRATES
8.5.6.1.1. UNITED
ARAB EMIRATES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5.6.2. TURKEY
8.5.6.2.1. TURKEY
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5.6.3. SAUDI
ARABIA
8.5.6.3.1. SAUDI
ARABIA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5.6.4. SOUTH
AFRICA
8.5.6.4.1. SOUTH AFRICA
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5.6.5. REST
OF MIDDLE EAST & AFRICA
8.5.6.5.1. REST
OF MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
9. COMPETITIVE
LANDSCAPE
9.1. ABBVIE
INC
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.1.3. KEY
STRENGTHS
9.1.4. KEY
CHALLENGES
9.2. BAUSCH
HEALTH COMPANIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY
CHALLENGES
9.3. JOHNSON
& JOHNSON
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY
STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. NOVARTIS
AG
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. REGENERON
PHARMACEUTICALS INC
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.5.3. KEY
STRENGTHS
9.5.4. KEY
CHALLENGES
9.6. SUN
PHARMACEUTICAL INDUSTRIES LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY
STRENGTHS
9.6.4. KEY
CHALLENGES
9.7. ACCUTOME
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY
STRENGTHS
9.7.4. KEY
CHALLENGES
9.8. GENENTECH
INC
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.8.3. KEY
STRENGTHS
9.8.4. KEY
CHALLENGES
9.9. THEA
PHARMA INC
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.9.3. KEY
STRENGTHS
9.9.4. KEY
CHALLENGES
9.10. PFIZER
INC
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY
STRENGTHS
9.10.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: GLOBAL OPHTHALMIC DRUGS MARKET, BY REGIONAL OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE 7: GLOBAL OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $
MILLION)
TABLE 8: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN
$ MILLION)
TABLE 9: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN
$ MILLION)
TABLE 10: GLOBAL OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN
$ MILLION)
TABLE 11: GLOBAL OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)
TABLE 12: GLOBAL OPHTHALMIC DRUGS MARKET, BY REGIONAL OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK,
2023-2030 (IN $ MILLION)
TABLE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030
(IN $ MILLION)
TABLE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2023-2030 (IN $ MILLION)
TABLE 17: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE,
2023-2030 (IN $ MILLION)
TABLE 18: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD,
2023-2030 (IN $ MILLION)
TABLE 19: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030
(IN $ MILLION)
TABLE 20: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE 21: EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE 22: EUROPE OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $
MILLION)
TABLE 23: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030
(IN $ MILLION)
TABLE 24: EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030
(IN $ MILLION)
TABLE 25: EUROPE OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030
(IN $ MILLION)
TABLE 26: EUROPE OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $
MILLION)
TABLE 27: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK,
2023-2030 (IN $ MILLION)
TABLE 28: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE 29: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030
(IN $ MILLION)
TABLE 30: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2023-2030 (IN $ MILLION)
TABLE 31: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE,
2023-2030 (IN $ MILLION)
TABLE 32: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD,
2023-2030 (IN $ MILLION)
TABLE 33: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN
$ MILLION)
TABLE 34: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK,
2023-2030 (IN $ MILLION)
TABLE 35: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE 36: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030
(IN $ MILLION)
TABLE 37: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2023-2030 (IN $ MILLION)
TABLE 38: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE,
2023-2030 (IN $ MILLION)
TABLE 39: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD,
2023-2030 (IN $ MILLION)
TABLE 40: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030
(IN $ MILLION)
TABLE 41: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY COUNTRY
OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 42: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE,
2023-2030 (IN $ MILLION)
TABLE 43: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CONDITION,
2023-2030 (IN $ MILLION)
TABLE 44: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY RETINAL
DISORDER, 2023-2030 (IN $ MILLION)
TABLE 45: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC
TYPE, 2023-2030 (IN $ MILLION)
TABLE 46: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DELIVERY
METHOD, 2023-2030 (IN $ MILLION)
TABLE 47: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CHANNEL,
2023-2030 (IN $ MILLION)
FIGURE 1: TECHNOLOGY SNAPSHOT
FIGURE 2: MARKET MATURITY ANALYSIS
FIGURE 3: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030 (IN %)
FIGURE 4: GLOBAL OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS,
2023-2030 (IN $ MILLION)
FIGURE 5: GLOBAL OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS,
2023-2030 (IN $ MILLION)
FIGURE 6: GLOBAL OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 & 2030
(IN %)
FIGURE 7: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030 (IN $
MILLION)
FIGURE 8: GLOBAL OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030 (IN $
MILLION)
FIGURE 9: GLOBAL OPHTHALMIC DRUGS MARKET, BY
INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)
FIGURE 10: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030
(IN $ MILLION)
FIGURE 11: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2022
& 2030 (IN %)
FIGURE 12: GLOBAL OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR
DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 13: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR
DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 14: GLOBAL OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY,
2023-2030 (IN $ MILLION)
FIGURE 15: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS,
2023-2030 (IN $ MILLION)
FIGURE 16: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS, 2023-2030
(IN $ MILLION)
FIGURE 17: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2022
& 2030 (IN %)
FIGURE 18: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2030
(IN $ MILLION)
FIGURE 19: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2030
(IN $ MILLION)
FIGURE 20: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY,
2023-2030 (IN $ MILLION)
FIGURE 21: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2030 (IN
$ MILLION)
FIGURE 22: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC TYPES,
2023-2030 (IN $ MILLION)
FIGURE 23: GLOBAL OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2022 &
2030 (IN %)
FIGURE 24: GLOBAL OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN $
MILLION)
FIGURE 25: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS &
SUSPENSIONS, 2023-2030 (IN $ MILLION)
FIGURE 26: GLOBAL OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS,
2023-2030 (IN $ MILLION)
FIGURE 27: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030 (IN $
MILLION)
FIGURE 28: GLOBAL OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030 (IN $
MILLION)
FIGURE 29: GLOBAL OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 & 2030
(IN %)
FIGURE 30: GLOBAL OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 31: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2030 (IN
$ MILLION)
FIGURE 32: GLOBAL OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 33: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS, 2023-2030
(IN $ MILLION)
FIGURE 34: GLOBAL OPHTHALMIC DRUGS MARKET, BY REGIONAL OUTLOOK, 2022
& 2030 (IN %)
FIGURE 35: UNITED STATES OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 36: CANADA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 37: UNITED KINGDOM OPHTHALMIC DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE 38: GERMANY OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 39: FRANCE OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 40: ITALY OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 41: SPAIN OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 42: POLAND OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 43: REST OF EUROPE OPHTHALMIC DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE 44: CHINA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 45: JAPAN OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 46: INDIA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 47: SOUTH KOREA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 48: ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE 49: AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET 2023-2030
(IN $ MILLION)
FIGURE 50: REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE 51: BRAZIL OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 52: MEXICO OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 53: REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE 54: UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE 55: TURKEY OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 56: SAUDI ARABIA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 57: SOUTH AFRICA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE 58: REST OF MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET
2023-2030 (IN $ MILLION)